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INTRODUCTION
As per the latest guidelines on probiotics contained in food or dietary supplements, strains must be selected from a ’’safe” species with 
enough evidence confirming the health benefits on the host. According to those latest recommendations, some data may possibly be 
extrapolated within the given bacterial species contained in the product, especially when it comes to taxonomy or functional 
comparisons. Such extrapolations, although financially sound, could be dangerous and open afield for assumptions or generalisations. 
We aimed to see whether drug sensitivity data within the Lactobacillus rhamnosus species is comparable for each of the 5 tested drugs, 
and whether extrapolation is acceptable or even appropriate, thus putting these recommendations in a new light and opening them up 
for discussion [1].
MATE RIAL AND METHODS
The Lactobacillus rhamnosus strains, contained in various probiotic preparations, were purchased commercially, exactly as available to 
the public. After gaining some previous experience regarding lactobacilli and drug sensitivity testing, including problems with zones of 
inhibition and resistant vs. sensitive breakpoints (Kochan etal. Antimicrobial resistance profiles of selected Polish probiotics, I PC 2010, 
Kosice, Slovak Republic)[2], we decided it's best to evaluate them using Etests. The following strains, were tested for drug sensitivity: 
L. rhamnosus GG, L. rhamnosus PEN, L. rhamnosus E/N, L. rhamnosus OXY and L. rhamnosus KL53A. We selected relatively novel 
drugs to be used in this study, namely: ceftaroline, ceftobiprole, doripenem, daptomycin and tigecycline. Tests were done in triplicates, to 
determine the minimal inhibitory concentration (MIC) and the final results were tabulated.
RESULTS
Results obtained showed high variability within the same Lactobacillus species for the tested antibiotics (Table 1). Depending on the 
antimicrobial which was evaluated, the MIC results were in a broad range from 0.002 to > 32 ug/ml, independent of the preparation they 
originated from or the producer, but dependent on the given strain. The MIC for the same drug within one single species were often 
strikingly different (Figure 1).
Table 1. Results of drug sensitivity testing of Lactobacillus rhamnosus 
strains using Etests. The table shows highly varied MIC values, within 
the same species. All species were sold in Poland as single or 
combined agents.
Etest
MIC (M g/m l)
L. rhamnosus 
GG
L. rhamnosus 
Pen
L. rhamnosus 
E/N
L. rhamnosus 
Oxy
L. rhamnosus 
KL53A
Ceftaroline
(CPT) 0.25 0.125 0.19 0.19 < 0.002
Ceftobiprole
(BPR) 0.38 >32 0.50 0.38 0.002
Doripenem
(DOR) 0.064 32 1 1 1
Daptomycin
(DPC) 12 8 48 24 12
Tigecycline
(TGC) 1.5 0.25 0.125 48 0.064
Figure 1. Significant differences regarding MIC and zones 
of inhibition, as shown using ceftaroline Etests and the disc 
diffusion test within the same L. rhamnosus species. Visit: www.wjomi.com
CONCLUSIONS
We were surprised to see that new probiotic recommendations allowed some field for extrapolation. Knowing that the devil lies in the 
details, in our study we wanted to try a different approach, aiming at individual strains in the same species. Despite the fact that the tested 
lactobacilli were strains from the same species, MIC values differed significantly for the same given drug.
We therefore propose that:
1. one should not extrapolate such important data related to drug sensitivity even within the same probiotic bacterial specie,
2. each probiotic bacterial strain should be tested for drug sensitivity since it's a strain specific characteristic.
One has to be careful in extrapolations and these results may in fact oppose the latest probiotic recommendations. We think that these 
results not only have some impact on the safety but also on the functionality of these strains (or more closely, the interplay between 
different gut bacteria and/or possible antibiotic resistance development in vivo).
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